Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.56 CHF | -0.05% | -2.23% | +16.78% |
05-22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
05-22 | Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.78% | 14.86B | |
+15.85% | 42.57B | |
+18.28% | 21.01B | |
+17.68% | 14.47B | |
+48.57% | 12.61B | |
-0.05% | 6.79B | |
-12.56% | 6.57B | |
+14.28% | 5.62B | |
+6.11% | 4.66B | |
+15.91% | 4.25B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Sandoz Upgrades Sandoz to Buy from Neutral, Boosts PT